@article{db54a56cc00f4c9fb452bd60859a7fe3,
title = "Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference",
abstract = "In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) published a guideline on the classification and management of acute kidney injury (AKI). The guideline was derived from evidence available through February 2011. Since then, new evidence has emerged that has important implications for clinical practice in diagnosing and managing AKI. In April of 2019, KDIGO held a controversies conference entitled Acute Kidney Injury with the following goals: determine best practices and areas of uncertainty in treating AKI; review key relevant literature published since the 2012 KDIGO AKI guideline; address ongoing controversial issues; identify new topics or issues to be revisited for the next iteration of the KDIGO AKI guideline; and outline research needed to improve AKI management. Here, we present the findings of this conference and describe key areas that future guidelines may address.",
keywords = "acute kidney disease, acute kidney injury, fluid management, nephrotoxicity, renal replacement therapy, risk stratification",
author = "Marlies Ostermann and Rinaldo Bellomo and Burdmann, {Emmanuel A.} and Kent Doi and Endre, {Zoltan H.} and Goldstein, {Stuart L.} and Kane-Gill, {Sandra L.} and Liu, {Kathleen D.} and Prowle, {John R.} and Shaw, {Andrew D.} and Nattachai Srisawat and Michael Cheung and Michel Jadoul and Winkelmayer, {Wolfgang C.} and Kellum, {John A.} and Bagshaw, {Sean M.} and Barreto, {Erin F.} and Azra Bihorac and Ilona Bobek and Jos{\'e}e Bouchard and Jorge Cerd{\'a} and Rajasekara Chakravarthi and {De Rosa}, Silvia and Engelman, {Daniel T.} and Forni, {Lui G.} and Hemmil{\"a}, {Ulla K.} and Herzog, {Charles A.} and Hoste, {Eric A.} and Huen, {Sarah C.} and Kunitoshi Iseki and Michael Joannidis and Kashani, {Kianoush B.} and Koyner, {Jay L.} and Andreas Kribben and Norbert Lameire and Levey, {Andrew S.} and Etienne Macedo and Jolanta Ma{\l}yszko and Melanie Meersch and Mehta, {Ravindra L.} and Irene Mewburn and Olga Mironova and Murray, {Patrick T.} and Nadim, {Mitra K.} and Pan, {Jenny S.} and Neesh Pannu and Zhiyong Peng and Barbara Philips and Daniela Ponce and Ray, {Patricio E.} and Zaccaria Ricci and Thomas Rimmel{\'e} and Claudio Ronco and Siew, {Edward D.} and Stevens, {Paul E.} and Tolwani, {Ashita J.} and Marcello Tonelli and Vaara, {Suvi T.} and {van Dam}, Marjel and Anitha Vijayan and Michael Wise and Wu, {Vin Cent} and Alexander Zarbock",
note = "Funding Information: This conference was sponsored by KDIGO and was in part supported by unrestricted educational grants from Akebia Therapeutics, AM-Pharma, Angion, AstraZeneca, Astute Medical, Atox Bio, Baxter, bioM{\'e}rieux, BioPorto, Boehringer Ingelheim, CytoSorbents, Edwards, Fresenius Medical Care, GE Healthcare, Grifols, Kyowa Kirin, Novartis, NxStage, Outset, and Potrero. Funding Information: MO declared having received consultancy fees from NxStage, speaker honoraria from Fresenius Medical Care, and research support from LaJolla Pharma. RB declared having received speaker honoraria from AbbVie and research support from Baxter. EAB declared having received consultancy fees from AstraZeneca and Fresenius Medical Care, and research support from Funda{\c c}{\~a}o de Amparo {\`a} Pesquisa do Estado de S{\~a}o Paulo. ZHE declared having received consultancy fees from AstraZeneca, and research support from Health Research Council of New Zealand and National University Hospital Singapore. SLG declared having received stock options from MediBeacon. KDL declared having received consultancy fees from bioM{\'e}rieux, speaker honoraria from Baxter, and stock options from Amgen. JRP declared having received consultancy fees from MediBeacon, Nikkiso Europe GmbH, and Quark Pharmaceuticals; speaker honoraria from Baxter, Fresenius Medical Care, and Nikkiso Europe GmbH; and research support from bioM{\'e}rieux. MJ declared having received consultancy fees from Amgen, AstraZeneca, Mundipharma, MSD, and Vifor Fresenius Medical Care Renal Pharma; speaker honoraria from Amgen, Menarini, MSD, and Vifor Fresenius Medical Care Renal Pharma; and research support from Amgen, MSD, and Otsuka. WCW declared having received consultancy fees from Akebia, AstraZeneca, Bayer, Janssen, Merck, Relypsa, and Vifor Fresenius Medical Care Renal Pharma; and research support from the National Institutes of Health. JAK declared having received consultancy fees from Astute Medical, Baxter, bioM{\'e}rieux, Davita, Fresenius Medical Care, Grifols, NxStage, Potrero, and RenalSense; and research support from Astute Medical, Baxter, bioM{\'e}rieux, and RenalSense. All the other authors declared no competing interests. Publisher Copyright: {\textcopyright} 2020 International Society of Nephrology",
year = "2020",
month = aug,
doi = "10.1016/j.kint.2020.04.020",
language = "English",
volume = "98",
pages = "294--309",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "2",
}